Panobinostat

Drug Profile

Panobinostat

Alternative Names: Farydak; LBH-589; LBH-589A

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Georgia Regents University; H. Lee Moffitt Cancer Center and Research Institute; HOVON Foundation; Mayo Clinic; National Cancer Institute (USA); New York University School of Medicine; Novartis; Peter MacCallum Cancer Centre; St. Jude Childrens Research Hospital; Therapeutic Advances in Childhood Leukemia & Lymphoma; Thomas Jefferson University; University of Aarhus; University of Texas M. D. Anderson Cancer Center; University of Wisconsin-Madison
  • Class Antineoplastics; Hydroxamic acids; Indoles; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II/III Chronic myeloid leukaemia
  • Phase II Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Graft-versus-host disease; Lymphoma; Myelodysplastic syndromes; Myelofibrosis; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Renal cell carcinoma; Thyroid cancer; Waldenstrom's macroglobulinaemia
  • Phase I/II Breast cancer; HIV-1 infections
  • Phase I Brain metastases; CNS cancer; Gastrointestinal stromal tumours; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Mantle-cell lymphoma; Non-small cell lung cancer; Solid tumours
  • Preclinical Small cell lung cancer
  • No development reported Glioma; Pancreatic cancer
  • Discontinued Cutaneous T cell lymphoma; Prostate cancer

Most Recent Events

  • 27 Oct 2016 Panobinostat (Intravenous formulation) is still in phase I/II trials for Graft-versus-host disease in USA (NCT01111526)
  • 03 Oct 2016 Novartis withdraws the PANORAMA-5 phase II trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, Austria, Argentina, Belgium, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Hong Kong, Italy, Netherlands, Singapore, Spain, Sweden, Switzerland and Thailand (PO), prior to enrolment (NCT02756663)
  • 15 Jul 2016 Novartis terminates a phase I/II trial in Renal cell carcinoma (Combination therapy, Metastatic disease, Inoperable/Unresectable) in USA (NCT01582009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top